• NPC1/USP7/p53 Axis Drives Cholesterol-Linked HCC Proliferati

  2026-07-28

  This study uncovers how the NPC1/USP7/p53 signaling axis orchestrates both cholesterol metabolism and cell proliferation in hepatocellular carcinoma (HCC). By elucidating the dual oncogenic role of NPC1 in destabilizing p53 tumor suppressor function and modulating cholesterol synthesis, the research identifies a promising targetable pathway for HCC intervention.

• Sulfo-NHS-SS-Biotin: Cleavable Labeling for Advanced Protein

  2026-07-28

  Sulfo-NHS-SS-Biotin enables precise, reversible cell surface protein labeling with unmatched aqueous solubility and cleavability. Its disulfide-linked biotin tag empowers dynamic affinity purification workflows, driving breakthroughs in proteostasis and membrane protein research.

• Dihydroartemisinin: Optimizing Bench Workflows from Artemisi

  2026-07-27

  Dihydroartemisinin stands apart as a high-purity Artemisia plant extract for advanced experimental workflows targeting malaria, inflammation, and cell signaling. This guide details robust use-cases, actionable protocols, and troubleshooting tips to help researchers unlock maximal value from APExBIO’s Dihydroartemisinin in both routine and cutting-edge assays.

• Nigericin as a Potassium/Hydrogen Ion Carrier: Oncology and

  2026-07-27

  Explore how Nigericin, a potent potassium/hydrogen ion carrier, bridges mitochondrial membrane dynamics with innovative anticancer and metabolic research. This article delivers novel insights into Nigericin’s mechanism, advanced assay design, and the implications for translational oncology.

• FAK Inhibitor 14: Optimizing Cancer Biology Research Workflo

  2026-07-26

  FAK Inhibitor 14 empowers researchers to dissect focal adhesion kinase signaling with precision, particularly in challenging models of cholesterol-resistant ovarian cancer. By integrating protocol enhancements and troubleshooting insights, this article bridges bench research with robust, reproducible experimental outcomes.

• Azathramycin A: Macrolide Antibiotic Solutions for TB Models

  2026-07-25

  Azathramycin A offers precision protein synthesis inhibition for Mycobacterium tuberculosis research, with unique workflow and troubleshooting considerations due to its instability and ribosome-targeting specificity. This guide delivers evidence-based protocol enhancements and advanced troubleshooting tips for maximizing assay reliability and translational power.

• Optimizing Cell Assays with CHIR-99021 (CT99021): Real-World

  2026-07-24

  This article addresses reproducibility and workflow challenges in cell viability and differentiation assays, focusing on how 'CHIR-99021 (CT99021)' (SKU A3011) from APExBIO delivers data-backed, selective GSK-3 inhibition. Scenario-driven guidance equips lab scientists to improve assay sensitivity, control signaling pathways, and select reliable reagents for robust stem cell research.

• Cathepsin B Inhibitor CA-074: Protocols and Workflow Guidanc

  2026-07-24

  Cathepsin B inhibitor CA-074 enables selective, nanomolar-range inhibition of cathepsin B, supporting precise dissection of proteolytic mechanisms in cancer metastasis, neurotoxicity, and immune regulation. It is best suited for cell-based and biochemical assays requiring minimal off-target effects and rapid, short-term inhibition. Not recommended for long-term stock storage in solution or use outside validated solubility ranges.

• Biotin-HPDP in Protein Palmitoylation & Tumor Immunometaboli

  2026-07-23

  Explore how Biotin-HPDP enables advanced thiol-specific protein labeling for studying palmitoylation and immune microenvironment dynamics in cancer. This article delivers unique insights beyond standard protocols, connecting biochemical technique to emerging immunotherapy targets.

• Sulfo-NHS-Biotin in Translational Protein Labeling Strategy

  2026-07-23

  This thought-leadership article explores the mechanistic, experimental, and translational advantages of Sulfo-NHS-Biotin for cell surface protein labeling in cutting-edge single-cell and cell therapy workflows. Integrating mechanistic insight and strategic guidance, it connects recent advances in nanovial-based single-cell functional screening to practical protocol design, while distinguishing APExBIO's Sulfo-NHS-Biotin as a benchmark reagent for translational researchers.

• Reduced NHE3 Activity Drives PEDV-Induced Diarrhea in Piglet

  2026-07-22

  This study demonstrates that acute porcine epidemic diarrhea virus (PEDV) infection impairs sodium absorption by specifically reducing membrane-associated NHE3 activity in neonatal piglet intestines. These mechanistic insights clarify why PEDV triggers severe diarrhea and provide a foundation for future research into targeted intervention strategies.

• CXCR4-Targeted Theranostics in Lymphoma: Imaging and Precisi

  2026-07-22

  This review highlights the theranostic potential of CXCR4-targeted imaging ligands and antagonists in lymphoma, emphasizing innovations in molecular diagnostics and precision therapy. The findings underscore how CXCR4 overexpression drives lymphoma progression, and detail advanced imaging and therapeutic strategies for improved disease management.

• UK-5099 in Immunometabolism: Protocol Insights and Assay Imp

  2026-07-21

  Explore how UK-5099 (PF-1005023) advances mitochondrial metabolism research through precise inhibition of the mitochondrial pyruvate carrier. This article reveals unique assay design strategies and protocol innovations for immunometabolic studies, offering new value beyond standard protocols.

• NHS-Biotin (A8002): Precision Amine-Reactive Protein Labelin

  2026-07-21

  NHS-Biotin, also known as N-hydroxysuccinimido biotin, is an amine-reactive biotinylation reagent that enables efficient and stable labeling of primary amine-containing biomolecules. Its membrane permeability and short spacer arm make it ideal for intracellular protein labeling and purification, with performance validated in advanced protein engineering and detection workflows.

• Aclacinomycin A: Dual Topoisomerase Inhibitor for Apoptosis

  2026-07-20

  Aclacinomycin A (Aclarubicin) is a validated dual topoisomerase I/II inhibitor and apoptosis inducer, widely used for reproducible DNA damage and cytotoxicity assays in cancer research. Potent activity is demonstrated in solid tumor and hematological malignancy models, with mechanistic benchmarks and protocol parameters well-documented in preclinical literature.

16861 records 1/1125 page Next 12345 下5页 Last page